Vertex Pharmaceuticals recently reported a significant revenue jump to $2,965 million in Q2 2025. Despite this success, the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

The Dow Jones Industrial Average rose 585.4 points, or 1.34%, at the open to 44173.64. The S&P 500 rose 91.93 points, or 1.47 ...

Discover how Vertex Pharmaceuticals achieved 12% Q2 2025 revenue growth with new launches like ALYFTREK, CASGEVY, & JOURNAVX.

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended ...

Three Motley Fool contributors believe they've found such unstoppable stocks with the "it" factor to buy in August -- and ...

Now, it’s worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

Vertex Pharmaceuticals is set to unveil its Q2 2025 earnings on August 4, highlighting its stronghold in rare disease ...

A new once-daily cystic fibrosis (CF) treatment trialled in Manchester has been approved for NHS use, following a recommendation made earlier this month by the National Institute for Health ...